Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated Lipodystrophy

This publication has 25 references indexed in Scilit:

• Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
  AIDS, 2000
• Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study
  AIDS, 2000
• A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
  AIDS, 1999
• Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
  The Lancet, 1999
• Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
  New England Journal of Medicine, 1999
• Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
  Nature Medicine, 1999
• Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
  AIDS, 1999
• Changing patterns of mortality across Europe in patients infected with HIV-1
  The Lancet, 1998
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
  AIDS, 1998
• Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
  New England Journal of Medicine, 1998